CHGCYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 04:59):

Stats
本日の出来高	87 113.00
平均出来高	178 107
時価総額	50.61B
EPS	$0 ( 2024-04-25 )
次の収益日	( $0 ) 2024-07-25
Last Dividend	$0.189 ( 2021-12-29 )
Next Dividend	$0 ( N/A )
P/E	24.03
ATR14	$0.0990 (0.64%)

ボリューム相関

長: -0.02 (neutral)

短: 0.58 (weak)

Signal:(51.07) Neutral

Chugai Pharmaceutical 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Chugai Pharmaceutical 相関 - 通貨/商品

0.10
( neutral )

0.31
( neutral )

0.00
( neutral )

-0.29
( neutral )

0.00
( neutral )

-0.28
( neutral )

Chugai Pharmaceutical 財務諸表

Annual	2023
収益:	$1 111.37B
総利益:	$693.01B (62.36 %)
EPS:	$197.83

FY	2023
収益:	$1 111.37B
総利益:	$693.01B (62.36 %)
EPS:	$197.83

FY	2022
収益:	$1 259.95B
総利益:	$783.70B (62.20 %)
EPS:	$227.64

FY	2021
収益:	$999.76B
総利益:	$661.61B (66.18 %)
EPS:	$92.15

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.61 - Stable (12.15%)

Information

First Dividend	$0.138	2020-12-29
Last Dividend	$0.189	2021-12-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.463	--
Avg. Dividend % Per Year	0.00%	--
Score	3.09	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.61
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-09-27)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
OVCHY	Ex Dividend Junior	2023-08-15	Annually	0.00%
DURYY	Ex Dividend Junior	2023-05-15	Annually	0.00%
TTNDY	Ex Dividend Knight	2023-08-28	Semi-Annually	0.00%
JMSB	Ex Dividend Junior	2023-06-26	Annually	0.00%
BORT	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
RGPCF	Ex Dividend Junior	2023-09-01	Semi-Annually	0.00%
FBPI	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
VTKLY	Ex Dividend Knight	2023-07-20	Semi-Annually	0.00%
LNVGY	Ex Dividend Knight	2023-07-26	Annually	0.00%
CKHGY	Ex Dividend Knight	2023-05-11	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	16 118	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.27	1.000	8.86	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00906	1.500	9.77	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.00175	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.61

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.